BioCentury
ARTICLE | Clinical News

ACH-3102: Additional Phase IIa data

March 17, 2014 7:00 AM UTC

Additional data from 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for 12 weeks led to an SVR 12 weeks after the end of treatment in 4 patients and an SVR 24 weeks after the end of treatment in 3 patients. Patients received 225 mg ACH-3102 on day 1 followed by 75 mg ACH-3102 once daily thereafter in combination with twice-daily ribavirin for 12 weeks. Data were presented at the Asia Pacific Association for the Study of the Liver meeting in Brisbane. Achillion reported SVR4 data from the trial last year (see BioCentury, Jan. 14, 2013 & April 29, 2013). ...